{"id":280,"date":"2023-02-23T10:00:00","date_gmt":"2023-02-23T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=280"},"modified":"2025-09-09T10:45:23","modified_gmt":"2025-09-09T10:45:23","slug":"china-bd-2023-kym-biosciences-keymed-lepu-and-astrazeneca-enters-license-on-claudin-18-2-adc-cmg901","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/280.html","title":{"rendered":"[China BD 2023] KYM Biosciences (Keymed \/ Lepu) and AstraZeneca Enters License on Claudin-18.2 ADC CMG901"},"content":{"rendered":"\n<p>Announced Date: 2023-02-23 (February 23, 2023)<\/p>\n\n\n\n<p>Asset Name: CMG901<\/p>\n\n\n\n<p>Licensor (Seller): KYM Biosciences (China) (joint venture established by Keymed Biosciences and Lepu Biopharma)<\/p>\n\n\n\n<p>Licensee (Buyer): AstraZeneca<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: antibody drug conjugate (ADC)<\/p>\n\n\n\n<p>Asset Target: Claudin-18.2<\/p>\n\n\n\n<p>Current Stage: Phase I<\/p>\n\n\n\n<p>Potential Indication: gastric cancer<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>AstraZeneca will be responsible for the research, development, manufacture and commercialisation of CMG901 globally.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Upfront payment of $63m,<\/p>\n\n\n\n<p>Development and sales-related milestone payments of up to $1.1bn.<\/p>\n\n\n\n<p>Tiered royalties up to low double digits.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/astrazeneca-enters-license-agreement-with-kym-biosciences-for-cmg901-a-claudin-182-antibody-drug-conjugate.html#\">AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name<\/p>\n\n\n\n<p>Keymed Biosciences \u5eb7\u8bfa\u4e9a\u751f\u7269<\/p>\n\n\n\n<p>Lepu Biopharma \u4e50\u666e\u751f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-02-23 (February 23, 2023) Asset Name: CMG901 Licensor (Seller): KYM Biosciences (China) (joint venture &hellip; <a title=\"[China BD 2023] KYM Biosciences (Keymed \/ Lepu) and AstraZeneca Enters License on Claudin-18.2 ADC CMG901\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/280.html\"><span class=\"screen-reader-text\">[China BD 2023] KYM Biosciences (Keymed \/ Lepu) and AstraZeneca Enters License on Claudin-18.2 ADC CMG901<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-280","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=280"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/280\/revisions"}],"predecessor-version":[{"id":282,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/280\/revisions\/282"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}